To determine whether BRAF, KRAS and NRAS mutations were associated with patients' outcomes, we analyzed association between overall survival and BRAF, KRAS and NRAS mutation status in 57 patients who had available follow up data including the well-recognized MM prognostic biomarkers, such as serum creatinine, hemoglobin, serum calcium and the ISS stage. The gene discussed is BRAF; the disease is Miyoshi myopathy.